Literature DB >> 2161579

Studies on vaccination against papillomaviruses: the immunity after infection and vaccination with bovine papillomaviruses of different types.

W F Jarrett1, B W O'Neil, J M Gaukroger, K T Smith, H M Laird, M S Campo.   

Abstract

Calves, free of antibodies to bovine papillomaviruses (BPV), were reared in isolation. One was infected with BPV-2, developed tumours and was resistant to homologous reinfection. Groups of calves were infected with BPV-2, BPV-5 or BPV-6; they all developed and subsequently rejected type-specific tumours. They were then infected with BPV-4; they were not immune and oral papillomas were induced. Groups of animals were vaccinated by intramuscular preparations of purified BPV-4 and BPV-6 and were challenged with homologous virus; all were immune to reinfection. An earlier experiment had shown this to be true for BPV-2. Two calves, immune to BPV-6, were not immune to BPV-1. These experiments, although they do not cover all the possibilities of reciprocal immunisation and challenge, indicate that prophylactic immunity to a range of papillomaviruses is type-specific. This is the first clear demonstration of this phenomenon in the papillomavirus group.

Entities:  

Mesh:

Year:  1990        PMID: 2161579

Source DB:  PubMed          Journal:  Vet Rec        ISSN: 0042-4900            Impact factor:   2.695


  16 in total

1.  Antibody responses elicited through homologous or heterologous prime-boost DNA and protein vaccinations differ in functional activity and avidity.

Authors:  Michael Vaine; Shixia Wang; Anthony Hackett; James Arthos; Shan Lu
Journal:  Vaccine       Date:  2010-02-17       Impact factor: 3.641

2.  Coinfection of human foreskin fragments with multiple human papillomavirus types (HPV-11, -40, and -LVX82/MM7) produces regionally separate HPV infections within the same athymic mouse xenograft.

Authors:  N D Christensen; W A Koltun; N M Cladel; L R Budgeon; C A Reed; J W Kreider; P A Welsh; S D Patrick; H Yang
Journal:  J Virol       Date:  1997-10       Impact factor: 5.103

Review 3.  [Prophylactic and therapeutic HPV immunization].

Authors:  M Müller; L Gissmann
Journal:  Hautarzt       Date:  2007-06       Impact factor: 0.751

Review 4.  The role of vaccines in the control of STDs: HPV vaccines.

Authors:  I H Frazer
Journal:  Genitourin Med       Date:  1996-12

5.  Production and characterization of human proliferative T-cell clones specific for human papillomavirus type 1 E4 protein.

Authors:  J C Steele; T Stankovic; P H Gallimore
Journal:  J Virol       Date:  1993-05       Impact factor: 5.103

Review 6.  Papillomavirus prophylactic vaccines: established successes, new approaches.

Authors:  M Saveria Campo; Richard B S Roden
Journal:  J Virol       Date:  2009-11-11       Impact factor: 5.103

Review 7.  Reflections on viruses and cancer.

Authors:  C Darcel
Journal:  Vet Res Commun       Date:  1994       Impact factor: 2.459

8.  Bovine cutaneous papillomas associated with bovine papillomavirus type 5.

Authors:  N Bloch; R H Sutton; P B Spradbrow
Journal:  Arch Virol       Date:  1994       Impact factor: 2.574

9.  Assessment of the serological relatedness of genital human papillomaviruses by hemagglutination inhibition.

Authors:  R B Roden; N L Hubbert; R Kirnbauer; N D Christensen; D R Lowy; J T Schiller
Journal:  J Virol       Date:  1996-05       Impact factor: 5.103

10.  Lack of effect of recombinant bovine interferon alpha I1 in the treatment of experimentally-induced bovine warts.

Authors:  M L Lassauzet; P A Salamin
Journal:  Can J Vet Res       Date:  1993-07       Impact factor: 1.310

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.